Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mark A. Enter"'
Autor:
Liang Kang, Andrea Worschech, Maria Libera Ascierto, Valeria De Giorgi, Mark A. Enter, Timothy J. O'Rourke, Francesco M. Marincola, Yanli Su, Curt J. Essenburg, Qian Xie, Lisa Kefene, George F. Vande Woude, Tom DeKoning, Dafna Kaufman, Julie Koeman, Ena Wang, Robert D. Bradley
Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5c452738bc0aa1d38d6e6e846628bd
https://europepmc.org/articles/PMC3258605/
https://europepmc.org/articles/PMC3258605/
Autor:
Liang Kang, Andrea Worschech, Mark A. Enter, Valeria De Giorgi, Curt J. Essenburg, Dafna Kaufman, Robert Bradley, Timothy J. O'Rourke, George F. Vande Woude, Ena Wang, Francesco M. Marincola, Qian Xie, Lisa Kefene, Yanli Su, Tom DeKoning, Julie Koeman
Publikováno v:
Cancer Research. 71:LB-223
Due to its invasive nature, glioblastoma (GBM) is the most aggressive brain cancer. Hepatocyte growth factor (HGF) binds to MET tyrosine kinase receptor and induces invasive tumor growth. As MET inhibitors are entering clinical trials against several